Steroids-dopamine interactions in the pathophysiology and treatment of cns disorders

CNS Neuroscience and Therapeutics

Volumn 16, Issue 3, 2010, Pages

  Sánchez, Maria Gabriela ^a,b   Bourque, Mélanie ^a,b   Morissette, Marc ^a,b   Di Paolo, Thérèse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Androgens; Dehydroepiandrosterone; Depression; Estradiol; Menopause; Parkinson's Disease; Progesterone, Schizophrenia

Indexed keywords

1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; 3 O METHYLDOPAMINE; AMINE OXIDASE (FLAVIN CONTAINING); ANDROGEN; BAZEDOXIFENE; DIARYLPROPIONITRILE; DOPAMINE; DOPAMINE 1 RECEPTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; GESTAGEN; LEVODOPA; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRASTERONE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; TAMOXIFEN; TESTOSTERONE; STEROID RECEPTOR;

BINDING SITE; BRADYKINESIA; BRAIN FUNCTION; BREAST CANCER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEPRESSION; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DYSKINESIA; ENVIRONMENTAL FACTOR; HALLUCINATION; HORMONAL THERAPY; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; LIMBIC SYSTEM; MENOPAUSE; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; PARKINSON DISEASE; PATHOGENESIS; PREGNANCY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INTERACTION; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REVIEW; RIGIDITY; SCHIZOPHRENIA; SEX DIFFERENCE; TARDIVE DYSKINESIA; TREMOR; AGING; ANIMAL; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE MODEL; DRUG EFFECTS; FEMALE; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SEXUAL DEVELOPMENT; SYNAPTIC TRANSMISSION;

AGING; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; RECEPTORS, STEROID; SEX CHARACTERISTICS; STEROIDS; SYNAPTIC TRANSMISSION;

EID: 77952173252     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00163.x     Document Type: Review

References (350)

1. Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM. Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implications. Steroids 2007 72 : 381 405.
2. McCullough LD, Hurn PD. Estrogen and ischemic neuroprotection: An integrated view. Trends Endocrinol Metab 2003 14 : 228 235.
3. Simpkins JW, Singh M. More than a decade of estrogen neuroprotection. Alzheimers Dement 2008 4 : S131 S136.
4. Veliskova J. Estrogens and epilepsy: Why are we so excited? Neuroscientist 2007 13 : 77 88.
5. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res 2002 57 : 357 384.
6. Carrer HF, Cambiasso MJ. Sexual differentiation of the brain: Genes, estrogen, and neurotrophic factors. Cell Mol Neurobiol 2002 22 : 479 500.
7. Maggi A, Ciana P, Belcredito S, Vegeto E. Estrogens in the nervous system: Mechanisms and nonreproductive functions. Annu Rev Physiol 2004 66 : 291 313.
8. Hampson E. Estrogen-related variations in human spatial and articulatory-motor skills. Psychoneuroendocrinology 1990 15 : 97 111.
9. Konishi K, Kumashiro M, Izumi H, Higuchi Y. Effects of the menstrual cycle on working memory: Comparison of postmenstrual and premenstrual phases. Ind Health 2008 46 : 253 260.
10. Konishi K, Kumashiro M, Izumi H, Higuchi Y, Awa Y. Effects of the menstrual cycle on language and visual working memory: A pilot study. Ind Health 2009 47 : 560 568.
11. Sherwin BB. Estrogen effects on cognition in menopausal women. Neurology 1997 48 : S21 S26.
12. Munro CA, McCaul ME, Wong DF, et al. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry 2006 59 : 966 974.
13. Di Forti M, Lappin JM, Murray RM. Risk factors for schizophrenia-all roads lead to dopamine. Eur Neuropsychopharmacol 2007 17 (Suppl 2 S101 S107.
14. Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol 2009 30 : 65 91.
15. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984 59 : 551 555.
16. Tannenbaum C, Barrett-Connor E, Laughlin GA, Platt RW. A longitudinal study of dehydroepiandrosterone sulphate (DHEAS) change in older men and women: The Rancho Bernardo Study. Eur J Endocrinol 2004 151 : 717 725.
17. van Os J, Kapur S. Schizophrenia. Lancet 2009 374 : 635 645.
18. Lindamer LA, Lohr JB, Harris MJ, Jeste DV. Gender, estrogen, and schizophrenia. Psychopharmacol Bull 1997 33 : 221 228.
19. Benes FM. Emerging principles of altered neural circuitry in schizophrenia. Brain Res Brain Res Rev 2000 31 : 251 269.
20. Dean B. Signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia. Aust N Z J Psychiatry 2000 34 : 560 569.
21. Fink G. The psychoprotective action of strogen is mediated by central serotonergic as well dopaminergic mechanisms. In : Takada, Curzon G, editors. Serotonin in the central nervous system and periphery.
22. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003 28 (Suppl 2 17 54.
23. Salokangas RK. Gender and the use of neuroleptics in schizophrenia. Schizophr Res 2004 66 : 41 49.
24. Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: Evidence from meta-analysis. Arch Gen Psychiatry 2003 60 : 565 571.
25. Kulkarni J, de Castella A, Fitzgerald PB, et al. Estrogen in severe mental illness: A potential new treatment approach. Arch Gen Psychiatry 2008 65 : 955 960.
26. Kulkarni J. Oestrogen - a new treatment approach for schizophrenia? Med J Aust 2009 190 : S37 S38.
27. Grigoriadis S, Seeman MV. The role of estrogen in schizophrenia: Implications for schizophrenia practice guidelines for women. Can J Psychiatry 2002 47 : 437 442.
28. Salokangas RK, Honkonen T, Saarinen S. Women have later onset than men in schizophrenia - but only in its paranoid form. Results of the DSP project. Eur Psychiatry 2003 18 : 274 281.
29. Bergemann N, Parzer P, Nagl I, et al. Acute psychiatric admission and menstrual cycle phase in women with schizophrenia. Arch Womens Ment Health 2002 5 : 119 126.
30. Huber TJ, Borsutzky M, Schneider U, Emrich HM. Psychotic disorders and gonadal function: Evidence supporting the oestrogen hypothesis. Acta Psychiatr Scand 2004 109 : 269 274.
31. Hochman KM, Lewine RR. Age of menarche and schizophrenia onset in women. Schizophr Res 2004 69 : 183 188.
32. Halari R, Kumari V, Mehrotra R, Wheeler M, Hines M, Sharma T. The relationship of sex hormones and cortisol with cognitive functioning in Schizophrenia. J Psychopharmacol 2004 18 : 366 374.
33. Huber TJ, Tettenborn C, Leifke E, Emrich HM. Sex hormones in psychotic men. Psychoneuroendocrinology 2005 30 : 111 114.
34. Kulkarni J, Riedel A, de Castella AR, et al. Estrogen - a potential treatment for schizophrenia. Schizophr Res 2001 48 : 137 144.
35. Riecher-Rossler A, Hafner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 1994 20 : 203 214.
36. Riecher-Rössler A. Estrogens in schizophrenia. In : Bergemann N, Riecher-Rössler A, editors. Estrogen effects in psychiatric disorders.
37. Hafner H, Behrens S, De Vry J, Gattaz WF. An animal model for the effects of estradiol on dopamine-mediated behavior: Implications for sex differences in schizophrenia. Psychiatry Res 1991 38 : 125 134.
38. Seeman MV. Current outcome in schizophrenia: Women vs men. Acta Psychiatr Scand 1986 73 : 609 617.
39. Seeman MV, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990 16 : 185 194.
40. Riecher-Rössler A, Hafner H. Gender aspects in schizophrenia: Bridging the border between social and biological psychiatry. Acta Psychiatr Scand 2000 407 (Suppl 102 58 62.
41. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: Epidemiology and treatment recommendations. Drugs Aging 2000 17 : 363 384.
42. Cetingok M, Chu CC, Park DB. The effect of culture on the sex differences in schizophrenia. Int J Soc Psychiatry 1990 36 : 272 279.
43. Rector NA, Seeman MV. Auditory hallucinations in women and men. Schizophr Res 1992 7 : 233 236.
44. Goldstein JM, Link BG. Gender and the expression of schizophrenia. J Psychiatr Res 1988 22 : 141 155.
45. Lewine R. Schizophrenia: An amotivational syndrome in men. Can J Psychiatry 1985 30 : 316 318.
46. Salem JE, Kring AM. The role of gender differences in the reduction of etiologic heterogeneity in schizophrenia. Clin Psychol Rev 1998 18 : 795 819.
47. Tamminga CA. Gender and schizophrenia. J Clin Psychiatry 1997 58 (Suppl 15 33 37.
48. Judd F, Armstrong S, Kulkarni J. Gender-sensitive mental health care. Australas Psychiatry 2009 17 : 105 111.
49. Lindamer LA, Lohr JB, Caligiuri MP, Jeste DV. Relationship of gender and age at onset of schizophrenia to severity of dyskinesia. J Neuropsychiatry Clin Neurosci 2001 13 : 399 402.
50. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: A critical review of the literature. Schizophr Bull 1992 18 : 701 715.
51. Glazer WM, Naftolin F, Moore DC, Bowers MB, MacLusky NJ. The relationship of circulating estradiol to tardive dyskinesia in men and postmenopausal women. Psychoneuroendocrinology 1983 8 : 429 434.
52. Turrone P, Seeman MV, Silvestri S. Estrogen receptor activation and tardive dyskinesia. Can J Psychiatry 2000 45 : 288 290.
53. Villeneuve A, Cazejust T, Cote M. Estrogens in tardive dyskinesia in male psychiatric patients. Neuropsychobiology 1980 6 : 145 151.
54. Villeneuve A, Langlier P, Bedard P. Estrogens, dopamine and dyskinesias. Can Psychiatr Assoc J 1978 23 : 68 70.
55. Koller WC, Barr A, Biary N. Estrogen treatment of dyskinetic disorders. Neurology 1982 32 : 547 549.
56. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 1996 20 : 247 252.
57. Erb JL, Kadane JB, Tourney G, et al. Discrimination between schizophrenic and control subjects by means of plasma dehydroepiandrosterone measurements. J Clin Endocrinol Metab 1981 52 : 181 186.
58. Oertel GW, Benes P, Schirazi M, Holzmann H, Hoffmann G. Interaction between dehydroepiandrosterone, cyclic adenosine-3',5'-monophosphate and glucose-6-phosphate-dehydrogenase in normal and diseased subjects. Experientia 1974 30 : 872 873.
59. Tourney G, Erb JL. Temporal variations in androgens and stress hormones in control and schizophrenic subjects. Biol Psychiatry 1979 14 : 395 404.
60. Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003 60 : 133 141.
61. Nachshoni T, Ebert T, Abramovitch Y, et al. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: A randomized, double-blind placebo controlled trial. Schizophr Res 2005 79 : 251 256.
62. Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: A randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychopharmacol 2006 26 : 495 499.
63. Haffen E, Sechter D. [The neurobiology of depression]. Rev Prat 1999 49 : 707 712.
64. Lieberman A. Depression in Parkinson's disease - a review. Acta Neurol Scand 2006 113 : 1 8.
65. Costa A, Peppe A, Carlesimo GA, Pasqualetti P, Caltagirone C. Major and minor depression in Parkinson's disease: A neuropsychological investigation. Eur J Neurol 2006 13 : 972 980.
66. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005 128 : 1314 1322.
67. Tessitore A, Hariri AR, Fera F, et al. Dopamine modulates the response of the human amygdala: A study in Parkinson's disease. J Neurosci 2002 22 : 9099 9103.
68. Elhwuegi AS. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004 28 : 435 451.
69. Usall i Rodié J. Use of estrogens in the treatment of mental disorders. Actas Esp. Psiquiatr 2003 4 : 199 204.
70. Archer JS. NAMS/Solvay Resident Essay Award. Relationship between estrogen, serotonin, and depression. Menopause 1999 6 : 71 78.
71. Buckwalter JG, Stanczyk FZ, McCleary CA, et al. Pregnancy, the postpartum, and steroid hormones: Effects on cognition and mood. Psychoneuroendocrinology 1999 24 : 69 84.
72. Rocca WA, Grossardt BR, Geda YE, et al. Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause 2008 15 : 1050 1059.
73. Studd J, Panay N. Are oestrogens useful for the treatment of depression in women? Best Pract Res Clin Obstet Gynaecol 2009 23 : 63 71.
74. Cyr M, Calon F, Morissette M, Grandbois M, Di Paolo T, Callier S. Drugs with estrogen-like potency and brain activity: Potential therapeutic application for the CNS. Curr Pharm Des 2000 6 : 1287 1312.
75. Dalla C, Antoniou K, Papadopoulou-Daifoti Z, Balthazart J, Bakker J. Oestrogen-deficient female aromatase knockout (ArKO) mice exhibit depressive-like symptomatology. Eur J Neurosci 2004 20 : 217 228.
76. Fink G, Sumner B, Rosie R, Wilson H, McQueen J. Androgen actions on central serotonin neurotransmission: Relevance for mood, mental state and memory. Behav Brain Res 1999 105 : 53 68.
77. Hill MN, Karacabeyli ES, Gorzalka BB. Estrogen recruits the endocannabinoid system to modulate emotionality. Psychoneuroendocrinology 2007 32 : 350 357.
78. Sugiyama N, Sasayama D, Amano N. Remarkable antidepressant augmentation effect of raloxifene, a selective estrogen receptor modulator, in a partial responder to fluvoxamine: A case report. J Clin Psychiatry 2007 68 : 636 637.
79. Turan MI, Gerhard L, Werner MH. Use of estradiol valerate as an anti-depressant. United States Patent 4330538 1982.
80. Young EA, Kornstein SG, Harvey AT, et al. Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology 2007 32 : 843 853.
81. Ahokas A, Kaukoranta J, Wahlbeck K, Aito M. Estrogen deficiency in severe postpartum depression: Successful treatment with sublingual physiologic 17beta-estradiol: A preliminary study. J Clin Psychiatry 2001 62 : 332 336.
82. Harlow BL, Wise LA, Otto MW, Soares CN, Cohen LS. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: The Harvard Study of Moods and Cycles. Arch Gen Psychiatry 2003 60 : 29 36.
83. Magos AL, Brincat M, Studd JW. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: Placebo controlled study. Br Med J (Clin Res Ed) 1986 292 : 1629 1633. (Pubitemid 16097868)
84. Rasgon NL, Altshuler LL, Fairbanks LA, et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry 2002 63 (Suppl 7 45 48.
85. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001 58 : 529 534.
86. Studd J, Zamblera D. Estrogen therapy in women over 60 years of age. Gynecol Endocrinol 1994 8 : 191 196.
87. Watson NR, Studd JW, Savvas M, Baber RJ. The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome. Gynecol Endocrinol 1990 4 : 99 107.
88. Watson NR, Studd JW, Savvas M, Garnett T, Baber RJ. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989 2 : 730 732.
89. Schmidt PJ, Murphy JH, Haq N, Danaceau MA, St Clair L. Basal plasma hormone levels in depressed perimenopausal women. Psychoneuroendocrinology 2002 27 : 907 920.
90. Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997 41 : 311 318.
91. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999 156 : 646 649.
92. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry 1999 45 : 1533 1541.
93. Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005 62 : 154 162.
94. Alves G, Muller B, Herlofson K, et al. Incidence of Parkinson's disease in Norway: The Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2009 80 : 851 857.
95. Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study: Two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000 55 : 1358 1363.
96. Czlonkowska A, Ciesielska A, Gromadzka G, Kurkowska-Jastrzebska I. Gender differences in neurological disease: Role of estrogens and cytokines. Endocrine 2006 29 : 243 256.
97. Kurtzke JF, Goldberg ID. Parkinsonism death rates by race, sex, and geography. Neurology 1988 38 : 1558 1561.
98. Marder K, Tang MX, Mejia H, et al. Risk of Parkinson's disease among first-degree relatives: A community-based study. Neurology 1996 47 : 155 160.
99. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 1992 49 : 492 497.
100. Mutch WJ, Dingwall-Fordyce I, Downie AW, Paterson JG, Roy SK. Parkinson's disease in a Scottish city. Br Med J (Clin Res Ed) 1986 292 : 534 536.
101. Shulman LM. Gender differences in Parkinson's disease. Gend Med 2007 4 : 8 18.
102. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity. Am J Epidemiol 2003 157 : 1015 1022.
103. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004 75 : 637 639.
104. de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: The Rotterdam Study. Neurology 1995 45 : 2143 2146.
105. Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007 78 : 819 824.
106. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study. Mov Disord 2001 16 : 830 837.
107. Ragonese P, D'Amelio M, Salemi G, et al. Risk of Parkinson disease in women: Effect of reproductive characteristics. Neurology 2004 62 : 2010 2014.
108. Saunders-Pullman R, Derby C, Santoro N, et al. Role of endogenous and exogenous hormone exposure on the risk of Parkinson disease. Annual meeting of American Academy of Neurology. Abstract S23.002, Seattle, Washington. 2009.
109. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004 61 : 886 888.
110. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003 60 : 790 795. (Pubitemid 36297362)
111. Popat RA, Van Den Eeden SK, Tanner CM, et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005 65 : 383 390.
112. Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Mov Disord 2009 24 : 1359 1365.
113. Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group. Neurology 1998 50 : 1327 1331.
114. Lyons KE, Hubble JP, Troster AI, Pahwa R, Koller WC. Gender differences in Parkinson's disease. Clin Neuropharmacol 1998 21 : 118 121.
115. Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: An exploratory study. Arch Neurol 2005 62 : 601 605.
116. Di Paolo T. Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 1994 5 : 27 41.
117. Giladi N, Honigman S. Hormones and Parkinson's disease. Neurology 1995 45 : 1028 1029.
118. Session DR, Pearlstone MM, Jewelewicz R, Kelly AC. Estrogens and Parkinson's disease. Med Hypotheses 1994 42 : 280 282.
119. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson's disease. Neurology 1999 52 : 1417 1421.
120. Strijks E, Kremer JA, Horstink MW. Effects of female sex steroids on Parkinson's disease in postmenopausal women. Clin Neuropharmacol 1999 22 : 93 97.
121. Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: A crossover study. Neurology 1999 53 : 91 95.
122. Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000 54 : 2292 2298.
123. Rubin SM. Parkinson's disease in women. Dis Mon 2007 53 : 206 213.
124. Kompoliti K, Comella CL, Jaglin JA, Leurgans S, Raman R, Goetz CG. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology 2000 55 : 1572 1575.
125. Quinn NP, Marsden CD. Menstrual-related fluctuations in Parkinson's disease. Mov Disord 1986 1 : 85 87.
126. Tolson D, Fleming V, Schartau E. Coping with menstruation: Understanding the needs of women with Parkinson's disease. J Adv Nurs 2002 40 : 513 521.
127. Golbe LI. Parkinson's disease and pregnancy. Neurology 1987 37 : 1245 1249.
128. Hagell P, Odin P, Vinge E. Pregnancy in Parkinson's disease: A review of the literature and a case report. Mov Disord 1998 13 : 34 38.
129. Robottom BJ, Mullins RJ, Shulman LM. Pregnancy in Parkinson's disease: Case report and discussion. Expert Rev Neurother 2008 8 : 1799 1805.
130. Shulman LM, Minagar A, Weiner WJ. The effect of pregnancy in Parkinson's disease. Mov Disord 2000 15 : 132 135.
131. Backman L, Nyberg L, Lindenberger U, Li SC, Farde L. The correlative triad among aging, dopamine, and cognition: Current status and future prospects. Neurosci Biobehav Rev 2006 30 : 791 807.
132. Becker JB, Rudick CN. Rapid effects of estrogen or progesterone on the amphetamine-induced increase in striatal dopamine are enhanced by estrogen priming: A microdialysis study. Pharmacol Biochem Behav 1999 64 : 53 57.
133. Thompson TL, Moss RL. Estrogen regulation of dopamine release in the nucleus accumbens: Genomic- and nongenomic-mediated effects. J Neurochem 1994 62 : 1750 1756.
134. Becker JB. Direct effect of 17 beta-estradiol on striatum: Sex differences in dopamine release. Synapse 1990 5 : 157 164.
135. Di Paolo T, Rouillard C, Bedard P. 17 beta-Estradiol at a physiological dose acutely increases dopamine turnover in rat brain. Eur J Pharmacol 1985 117 : 197 203.
136. Castner SA, Xiao L, Becker JB. Sex differences in striatal dopamine: In vivo microdialysis and behavioral studies. Brain Res 1993 610 : 127 134.
137. Morissette M, Di Paolo T. Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys. J Neurosci Res 2009 87 : 1634 1644.
138. Wood PL, Altar CA. Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons: Utility of 3-methoxytyramine measurements. Pharmacol Rev 1988 40 : 163 187.
139. Levesque D, Di Paolo T. Effect of the rat estrous cycle at ovariectomy on striatal D-1 dopamine receptors. Brain Res Bull 1990 24 : 281 284.
140. Levesque D, Gagnon S, Di Paolo T. Striatal D1 dopamine receptor density fluctuates during the rat estrous cycle. Neurosci Lett 1989 98 : 345 350.
141. Bosse R, DiPaolo T. The modulation of brain dopamine and GABAA receptors by estradiol: A clue for CNS changes occurring at menopause. Cell Mol Neurobiol 1996 16 : 199 212.
142. Di Paolo T, Falardeau P, Morissette M. Striatal D-2 dopamine agonist binding sites fluctuate during the rat estrous cycle. Life Sci 1988 43 : 665 672.
143. Nordstrom AL, Olsson H, Halldin C. A PET study of D2 dopamine receptor density at different phases of the menstrual cycle. Psychiatry Res 1998 83 : 1 6.
144. Ursic M, Bavdek SV, Zabavnik J. The number of cells expressing dopamine D2 receptor mRNA in rat brain caudate putamen is higher in oestrus. J Anat 2003 202 : 453 461.
145. Landry M, Levesque D, Di Paolo T. Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 2002 76 : 214 222.
146. Lammers CH, D'Souza U, Qin ZH, Lee SH, Yajima S, Mouradian MM. Regulation of striatal dopamine receptors by estrogen. Synapse 1999 34 : 222 227.
147. Zhou W, Cunningham KA, Thomas ML. Estrogen regulation of gene expression in the brain: A possible mechanism altering the response to psychostimulants in female rats. Brain Res Mol Brain Res 2002 100 : 75 83.
148. Levesque D, Di Paolo T. Modulation by estradiol and progesterone of the GTP effect on striatal D-2 dopamine receptors. Biochem Pharmacol 1993 45 : 723 733.
149. Bosse R, Rivest R, Di Paolo T. Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain. Brain Res Mol Brain Res 1997 46 : 343 346.
150. Le Saux M, Di Paolo T. Influence of oestrogenic compounds on monoamine transporters in rat striatum. J Neuroendocrinol 2006 18 : 25 32.
151. Morissette M, Di Paolo T. Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites. J Neurochem 1993 60 : 1876 1883.
152. Attali G, Weizman A, Gil-Ad I, Rehavi M. Opposite modulatory effects of ovarian hormones on rat brain dopamine and serotonin transporters. Brain Res 1997 756 : 153 159.
153. Gardiner SA, Morrison MF, Mozley PD, et al. Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy, postmenopausal women. Am J Geriatr Psychiatry 2004 12 : 621 630.
154. Rehavi M, Goldin M, Roz N, Weizman A. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones. Brain Res Mol Brain Res 1998 57 : 31 37.
155. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003 184 (Suppl 1 S68 79.
156. Petitclerc M, Bedard PJ, Di Paolo T. Progesterone releases dopamine in male and female rat striatum: A behavioral and microdialysis study. Prog Neuropsychopharmacol Biol Psychiatry 1995 19 : 491 497.
157. Dluzen DE, Ramirez VD. Bimodal effect of progesterone on in vitro dopamine function of the rat corpus striatum. Neuroendocrinology 1984 39 : 149 155.
158. Dluzen DE, Ramirez VD. Progesterone effects upon dopamine release from the corpus striatum of female rats. II. Evidence for a membrane site of action and the role of albumin. Brain Res 1989 476 : 338 344.
159. Cabrera R, Diaz A, Pinter A, Belmar J. In vitro progesterone effects on 3H-dopamine release from rat corpus striatum slices obtained under different endocrine conditions. Life Sci 1993 53 : 1767 1777.
160. Di Paolo T, Levesque D, Daigle M. A physiological dose of progesterone affects rat striatum biogenic amine metabolism. Eur J Pharmacol 1986 125 : 11 16.
161. Morissette M, Biron D, Di Paolo T. Effect of estradiol and progesterone on rat striatal dopamine uptake sites. Brain Res Bull 1990 25 : 419 422. (Pubitemid 20346576)
162. Fernandez-Ruiz JJ, Amor JC, Ramos JA. Time-dependent effects of estradiol and progesterone on the number of striatal dopaminergic D2-receptors. Brain Res 1989 476 : 388 395.
163. de Souza Silva MA, Mattern C, Topic B, Buddenberg TE, Huston JP. Dopaminergic and serotonergic activity in neostriatum and nucleus accumbens enhanced by intranasal administration of testosterone. Eur Neuropsychopharmacol 2009 19 : 53 63.
164. Thiblin I, Finn A, Ross SB, Stenfors C. Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids. Br J Pharmacol 1999 126 : 1301 1306.
165. Bitar MS, Ota M, Linnoila M, Shapiro BH. Modification of gonadectomy-induced increases in brain monoamine metabolism by steroid hormones in male and female rats. Psychoneuroendocrinology 1991 16 : 547 557.
166. Tomas-Camardiel M, Sanchez-Hidalgo MC, Sanchez del Pino MJ, Navarro A, Machado A, Cano J. Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17beta-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum. Neuroscience 2002 109 : 569 584.
167. Shemisa K, Kunnathur V, Liu B, Salvaterra TJ, Dluzen DE. Testosterone modulation of striatal dopamine output in orchidectomized mice. Synapse 2006 60 : 347 353.
168. Meyers B, Kritzer MF. In vitro binding assays using (3)H nisoxetine and (3)H WIN 35,428 reveal selective effects of gonadectomy and hormone replacement in adult male rats on norepinephrine but not dopamine transporter sites in the cerebral cortex. Neuroscience 2009 159 : 271 282.
169. Andersen SL, Thompson AP, Krenzel E, Teicher MH. Pubertal changes in gonadal hormones do not underlie adolescent dopamine receptor overproduction. Psychoneuroendocrinology 2002 27 : 683 691.
170. Guivarc'h D, Vernier P, Vincent JD. Sex steroid hormones change the differential distribution of the isoforms of the D2 dopamine receptor messenger RNA in the rat brain. Neuroscience 1995 69 : 159 166.
171. Murray HE, Gillies GE. Differential effects of neuroactive steroids on somatostatin and dopamine secretion from primary hypothalamic cell cultures. J Neuroendocrinol 1997 9 : 287 295.
172. Perez-Neri I, Mendez-Sanchez I, Montes S, Rios C. Acute dehydroepiandrosterone treatment exerts different effects on dopamine and serotonin turnover ratios in the rat corpus striatum and nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiatry 2008 32 : 1584 1589.
173. Perez-Neri I, Montes S, Rios C. Inhibitory effect of dehydroepiandrosterone on brain monoamine oxidase activity: In vivo and in vitro studies. Life Sci 2009 85 : 652 656.
174. Muneoka K, Iwata M, Shirayama Y. Altered levels of synapsin I, dopamine transporter, dynorphin A, and neuropeptide Y in the nucleus accumbens and striatum at post-puberty in rats treated neonatally with pregnenolone or DHEA. Int J Dev Neurosci 2009 27 : 575 581.
175. Bourque M, Dluzen DE, Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol 2009 30 : 142 157.
176. Dluzen DE, McDermott JL, Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 1996 18 : 603 606.
177. Miller DB, Ali SF, O'Callaghan JP, Laws SC. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann N Y Acad Sci 1998 844 : 153 165.
178. Murray HE, Pillai AV, McArthur SR, et al. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: Differential actions of estrogen in males and females. Neuroscience 2003 116 : 213 222.
179. Wagner GC, Tekirian TL, Cheo CT. Sexual differences in sensitivity to methamphetamine toxicity. J Neural Transm Gen Sect 1993 93 : 67 70.
180. Yu L, Liao PC. Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice. J Neural Transm 2000 107 : 419 427.
181. Datla KP, Murray HE, Pillai AV, Gillies GE, Dexter DT. Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. Neuroreport 2003 14 : 47 50.
182. Callier S, Morissette M, Grandbois M, Di Paolo T. Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice. Synapse 2000 37 : 245 251. (Pubitemid 30613021)
183. Callier S, Morissette M, Grandbois M, Pelaprat D, Di Paolo T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 2001 41 : 131 138.
184. D'Astous M, Morissette M, Callier S, Di Paolo T. Regulation of striatal preproenkephalin mRNA levels in MPTP-lesioned mice treated with estradiol. J Neurosci Res 2005 80 : 138 144.
185. D'Astous M, Morissette M, Tanguay B, Callier S, Di Paolo T. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice. Synapse 2003 47 : 10 14.
186. Ekue A, Boulanger JF, Morissette M, Di Paolo T. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice. J Neuroendocrinol 2002 14 : 731 736.
187. Jourdain S, Morissette M, Morin N, Di Paolo T. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. J Neuroendocrinol 2005 17 : 509 517.
188. Morissette M, Al Sweidi S, Callier S, Di Paolo T. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol Cell Endocrinol 2008 290 : 60 69.
189. Ramirez AD, Liu X, Menniti FS. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 2003 77 : 223 231.
190. Ookubo M, Yokoyama H, Takagi S, Kato H, Araki T. Effects of estrogens on striatal damage after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in male and female mice. Mol Cell Endocrinol 2008 296 : 87 93.
191. D'Astous M, Gajjar TM, Dluzen DE, Di Paolo T. Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol. Neuroendocrinology 2004 79 : 296 304.
192. D'Astous M, Mickley KR, Dluzen DE, Di Paolo T. Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice. Neuroendocrinology 2005 82 : 111 120.
193. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res 1997 767 : 340 344.
194. Dluzen DE, Anderson LI, Pilati CF. Methamphetamine-gonadal steroid hormonal interactions: Effects upon acute toxicity and striatal dopamine concentrations. Neurotoxicol Teratol 2002 24 : 267 273.
195. Gajjar TM, Anderson LI, Dluzen DE. Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. J Neural Transm 2003 110 : 1215 1224.
196. Gao X, Dluzen DE. The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Brain Res 2001 892 : 63 69.
197. Mickley KR, Dluzen DE. Dose-response effects of estrogen and tamoxifen upon methamphetamine-induced behavioral responses and neurotoxicity of the nigrostriatal dopaminergic system in female mice. Neuroendocrinology 2004 79 : 305 316.
198. Peinado V, Gonzalez JC, Leret ML. Effect of 17-beta-estradiol on dopamine, serotonine and GABA striatal levels in 6-hydroxydopamine-treated rats. Toxicology 2004 204 : 155 160.
199. Gillies GE, Murray HE, Dexter D, McArthur S. Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease. Pharmacol Biochem Behav 2004 78 : 513 522.
200. Anderson LI, Leipheimer RE, Dluzen DE. Effects of neonatal and prepubertal hormonal manipulations upon estrogen neuroprotection of the nigrostriatal dopaminergic system within female and male mice. Neuroscience 2005 130 : 369 382.
201. Ferraz AC, Matheussi F, Szawka RE, et al. Evaluation of estrogen neuroprotective effect on nigrostriatal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars compacta or the medial forebrain bundle. Neurochem Res 2008 33 : 1238 1246.
202. Gao X, Dluzen DE. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 2001 103 : 385 394. (Pubitemid 32201925)
203. Dluzen DE, McDermott JL, Anderson LI. Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system. Neurotox Res 2001 3 : 291 300.
204. Fumagalli F, Gainetdinov RR, Valenzano KJ, Caron MG. Role of dopamine transporter in methamphetamine-induced neurotoxicity: Evidence from mice lacking the transporter. J Neurosci 1998 18 : 4861 4869.
205. Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 1999 19 : 2424 2431.
206. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG. Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter. J Neurochem 1997 69 : 1322 1325.
207. Gainetdinov RR, Fumagalli F, Wang YM, et al. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J Neurochem 1998 70 : 1973 1978.
208. Bourque M, Liu B, Dluzen DE, Di Paolo T. Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity. Biochem Pharmacol 2007 74 : 1413 1423.
209. Bywood PT, Johnson SM. Dendrite loss is a characteristic early indicator of toxin-induced neurodegeneration in rat midbrain slices. Exp Neurol 2000 161 : 306 316.
210. Grandbois M, Morissette M, Callier S, Di Paolo T. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuroreport 2000 11 : 343 346. (Pubitemid 30074646)
211. Yu L, Kuo Y, Cherng CG, Chen HH, Hsu CH. Ovarian hormones do not attenuate methamphetamine-induced dopaminergic neurotoxicity in mice gonadectomized at 4 weeks postpartum. Neuroendocrinology 2002 75 : 282 287.
212. Yu L, Liao PC. Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice. J Neural Transm 2000 107 : 1139 1147.
213. Dluzen DE. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice. Brain Res 1996 715 : 113 118.
214. Lewis C, Dluzen DE. Testosterone enhances dopamine depletion by methamphetamine in male, but not female, mice. Neurosci Lett 2008 448 : 130 133.
215. Liu B, Dluzen DE. Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice. Neuroendocrinology 2006 83 : 295 302.
216. Grese TA, Pennington LD, Sluka JP, et al. Synthesis and pharmacology of conformationally restricted raloxifene analogues: Highly potent selective estrogen receptor modulators. J Med Chem 1998 41 : 1272 1283.
217. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004 291 : 1701 1712.
218. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002 288 : 321 333.
219. Sherwin BB. The critical period hypothesis: Can it explain discrepancies in the oestrogen-cognition literature? J Neuroendocrinol 2007 19 : 77 81.
220. Singh M. Progestins and neuroprotection: Are all progestins created equal? Minerva Endocrinol 2007 32 : 95 102.
221. Doncarlos LL, Azcoitia I, Garcia-Segura LM. Neuroprotective actions of selective estrogen receptor modulators. Psychoneuroendocrinology 2009 34 (Suppl 1 S113 S122.
222. Ciriza I, Carrero P, Azcoitia I, Lundeen SG, Garcia-Segura LM. Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitotoxicity: Differences with the effect of estradiol. J Neurobiol 2004 61 : 209 221.
223. Dhandapani KM, Brann DW. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod 2002 67 : 1379 1385.
224. Kimelberg HK, Jin Y, Charniga C, Feustel PJ. Neuroprotective activity of tamoxifen in permanent focal ischemia. J Neurosurg 2003 99 : 138 142.
225. Kokiko ON, Murashov AK, Hoane MR. Administration of raloxifene reduces sensorimotor and working memory deficits following traumatic brain injury. Behav Brain Res 2006 170 : 233 240.
226. Mehta SH, Dhandapani KM, De Sevilla LM, Webb RC, Mahesh VB, Brann DW. Tamoxifen, a selective estrogen receptor modulator, reduces ischemic damage caused by middle cerebral artery occlusion in the ovariectomized female rat. Neuroendocrinology 2003 77 : 44 50.
227. Rossberg MI, Murphy SJ, Traystman RJ, Hurn PD. LY353381.HCl, a selective estrogen receptor modulator, and experimental stroke. Stroke 2000 31 : 3041 3046.
228. Zhao L, O'Neill K, Brinton RD. Estrogenic agonist activity of ICI 182,780 (Faslodex) in hippocampal neurons: Implications for basic science understanding of estrogen signaling and development of estrogen modulators with a dual therapeutic profile. J Pharmacol Exp Ther 2006 319 : 1124 1132.
229. Zhao L, O'Neill K, Diaz Brinton R. Selective estrogen receptor modulators (SERMs) for the brain: Current status and remaining challenges for developing NeuroSERMs. Brain Res Brain Res Rev 2005 49 : 472 493.
230. Azcoitia I, Moreno A, Carrero P, Palacios S, Garcia-Segura LM. Neuroprotective effects of soy phytoestrogens in the rat brain. Gynecol Endocrinol 2006 22 : 63 69.
231. Cyr M, Calon F, Morissette M, Di Paolo T. Estrogenic modulation of brain activity: Implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci 2002 27 : 12 27.
232. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997 138 : 863 870. (Pubitemid 27089735)
233. Anthony M, Williams JK, Dunn BK. What would be the properties of an ideal SERM? Ann N Y Acad Sci 2001 949 : 261 278.
234. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998 16 : 501 514.
235. Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 1998 152 : 396 411.
236. Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens. J Clin Oncol 1997 15 : 840 852.
237. Robinson E, Kimmick GG, Muss HB. Tamoxifen in postmenopausal women a safety perspective. Drugs Aging 1996 8 : 329 337.
238. Shariff S, Cumming CE, Lees A, Handman M, Cumming DC. Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist. An expected or unexpected effect? Ann N Y Acad Sci 1995 761 : 365 368.
239. Cathcart CK, Jones SE, Pumroy CS, Peters GN, Knox SM, Cheek JH. Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 1993 27 : 277 281.
240. Hiemke C, Ghraf R. Interaction of non-steroidal antiestrogens with dopamine receptor binding. J Steroid Biochem 1984 21 : 663 667.
241. Toney TW, Katzenellenbogen BS. An evaluation of the interactions of antiestrogens with pituitary and striatal dopamine receptors. J Recept Res 1987 7 : 695 712.
242. Ferretti C, Blengio M, Ghi P, Racca S, Genazzani E, Portaleone P. Tamoxifen counteracts estradiol induced effects on striatal and hypophyseal dopamine receptors. Life Sci 1988 42 : 2457 2465.
243. McDermott JL, Anderson LI, Dluzen DE. Interactive effects of tamoxifen and estrogen upon the nigrostriatal dopaminergic system. Neuroendocrinology 1997 66 : 181 187.
244. McDermott JL, Anderson LI, Dluzen DE. Tamoxifen alters dopamine output through direct actions upon superfused corpus striatal tissue fragments. Neurochem Int 1998 32 : 299 307.
245. McDermott JL, Anderson LI, Dluzen DE. Interactive effects of tamoxifen and oestrogen upon the nigrostriatal dopaminergic system: Long-term treatments. J Neuroendocrinol 1999 11 : 801 803.
246. McDermott JL, Liu B, Dluzen DE. Tamoxifen treatment of ovariectomized mice alters dopamine release from striatal tissue fragments superfused in vitro. Brain Res 1995 698 : 248 252.
247. Nicoletti F, Speciale C, Sortino MA, Panetta MS, Di Giorgio RM, Canonico PL. Estrogen effects on nigral glutamic acid decarboxylase activity: A possible role for catecholestrogen. Eur J Pharmacol 1985 115 : 297 300.
248. Chaurasia CS, Chen CE, Rubin J, Dewey SL. Effects of tamoxifen on striatal dopamine and 5-hydroxytryptamine release in freely moving male rats: An in-vivo microdialysis investigation. J Pharm Pharmacol 1998 50 : 1377 1385.
249. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998 139 : 4252 4263.
250. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997 337 : 1641 1647.
251. Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: The Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005 162 : 683 690.
252. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev 2001 81 : 1535 1565.
253. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999 20 : 279 307.
254. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J Comp Neurol 1997 388 : 507 525.
255. Li X, Schwartz PE, Rissman EF. Distribution of estrogen receptor-beta-like immunoreactivity in rat forebrain. Neuroendocrinology 1997 66 : 63 67.
256. Shughrue P, Scrimo P, Lane M, Askew R, Merchenthaler I. The distribution of estrogen receptor-beta mRNA in forebrain regions of the estrogen receptor-alpha knockout mouse. Endocrinology 1997 138 : 5649 5652.
257. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, Katzenellenbogen BS. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol 2003 206 : 13 22.
258. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 2002 143 : 4172 4177.
259. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor-beta potency-selective ligands: Structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 2001 44 : 4230 4251.
260. Frasor J, Barnett DH, Danes JM, Hess R, Parlow AF, Katzenellenbogen BS. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. Endocrinology 2003 144 : 3159 3166.
261. Lund TD, Rovis T, Chung WC, Handa RJ. Novel actions of estrogen receptor-beta on anxiety-related behaviors. Endocrinology 2005 146 : 797 807.
262. Waters EM, Mitterling K, Spencer JL, Mazid S, McEwen BS, Milner TA. Estrogen receptor alpha and beta specific agonists regulate expression of synaptic proteins in rat hippocampus. Brain Res 2009 1290 : 1 11.
263. Frye CA, Duffy CK, Walf AA. Estrogens and progestins enhance spatial learning of intact and ovariectomized rats in the object placement task. Neurobiol Learn Mem 2007 88 : 208 216.
264. Walf AA, Koonce CJ, Frye CA. Estradiol or diarylpropionitrile administration to wild type, but not estrogen receptor beta knockout, mice enhances performance in the object recognition and object placement tasks. Neurobiol Learn Mem 2008 89 : 513 521.
265. Walf AA, Rhodes ME, Frye CA. Antidepressant effects of ERbeta-selective estrogen receptor modulators in the forced swim test. Pharmacol Biochem Behav 2004 78 : 523 529.
266. Weiser MJ, Wu TJ, Handa RJ. Estrogen receptor-beta agonist diarylpropionitrile: Biological activities of R- and S-enantiomers on behavior and hormonal response to stress. Endocrinology 2009 150 : 1817 1825.
267. Le Saux M, Morissette M, Di Paolo T. ERbeta mediates the estradiol increase of D2 receptors in rat striatum and nucleus accumbens. Neuropharmacology 2006 50 : 451 457.
268. Morissette M, Le Saux M, D'Astous M, et al. Contribution of estrogen receptors alpha and beta to the effects of estradiol in the brain. J Steroid Biochem Mol Biol 2008 108 : 327 338.
269. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005 307 : 1625 1630.
270. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005 146 : 624 632.
271. Olde B, Leeb-Lundberg LM. GPR30/GPER1: Searching for a role in estrogen physiology. Trends Endocrinol Metab 2009 20 : 409 416.
272. Otto C, Fuchs I, Kauselmann G, et al. GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol Reprod 2009 80 : 34 41.
273. Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 2006 20 : 1996 2009. (Pubitemid 44286700)
274. Brailoiu E, Dun SL, Brailoiu GC, et al. Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J Endocrinol 2007 193 : 311 321.
275. Funakoshi T, Yanai A, Shinoda K, Kawano MM, Mizukami Y. G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Commun 2006 346 : 904 910.
276. Matsuda K, Sakamoto H, Mori H, et al. Expression and intracellular distribution of the G protein-coupled receptor 30 in rat hippocampal formation. Neurosci Lett 2008 441 : 94 99.
277. Prossnitz ER, Barton M. Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostaglandins Other Lipid Mediat 2009 89 : 89 97.
278. Thomas P, Dong J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: A potential novel mechanism of endocrine disruption. J Steroid Biochem Mol Biol 2006 102 : 175 179.
279. Bologa CG, Revankar CM, Young SM, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006 2 : 207 212.
280. Dennis MK, Burai R, Ramesh C, et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol 2009 5 : 421 427.
281. Windahl SH, Andersson N, Chagin AS, et al. The role of the G protein-coupled receptor GPR30 in the effects of estrogen in ovariectomized mice. Am J Physiol Endocrinol Metab 2009 296 : E490 496.
282. Do Rego JL, Seong JY, Burel D, et al. Neurosteroid biosynthesis: Enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides. Front Neuroendocrinol 2009 30 : 259 301.
283. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial. J Clin Endocrinol Metab 2004 89 : 3841 3846.
284. Osterlund MK, Witt MR, Gustafsson JA. Estrogen action in mood and neurodegenerative disorders: Estrogenic compounds with selective properties - the next generation of therapeutics. Endocrine 2005 28 : 235 242.
285. Garcia-Segura LM, Sanz A, Mendez P. Cross-talk between IGF-I and estradiol in the brain: Focus on neuroprotection. Neuroendocrinology 2006 84 : 275 279.
286. Wright DW, Kellermann AL, Hertzberg VS, et al. ProTECT: A randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2007 49 : 391 402, 402 e391 e392.
287. Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: A randomized controlled trial. Crit Care 2008 12 : R61.
288. Brinton RD, Thompson RF, Foy MR, et al. Progesterone receptors: Form and function in brain. Front Neuroendocrinol 2008 29 : 313 339.
289. Zheng P. Neuroactive steroid regulation of neurotransmitter release in the CNS: Action, mechanism and possible significance. Prog Neurobiol 2009 89 : 134 152.
290. MacDonald AW, Schulz SC. What we know: Findings that every theory of schizophrenia should explain. Schizophr Bull 2009 35 : 493 508.
291. McGrath JJ, Susser ES. New directions in the epidemiology of schizophrenia. Med J Aust 2009 190 : S7 S9.
292. Afifi M. Gender differences in mental health. Singapore Med J 2007 48 : 385 391.
293. Salokangas RK. Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis. Schizophr Res 1995 16 : 7 16.
294. Brummelte S, Galea LA. Depression during pregnancy and postpartum: Contribution of stress and ovarian hormones. Prog Neuropsychopharmacol Biol Psychiatry 2009 Epub ahead of print HD, Jann MW. Major depression in women: A review of the literature. J Am Pharm Assoc (Wash) 2000 40 : 525 537.
295. Gutierrez-Lobos K, Scherer M, Anderer P, Katschnig H. The influence of age on the female/male ratio of treated incidence rates in depression. BMC Psychiatry 2002 2 : 3.
296. Sloan DM, Kornstein SG. Gender differences in depression and response to antidepressant treatment. Psychiatr Clin North Am 2003 26 : 581 594.
297. Zender R, Olshansky E. Women's mental health: Depression and anxiety. Nurs Clin North Am 2009 44 : 355 364.
298. Young E, Korszun A. Sex, trauma, stress hormones and depression. Mol Psychiatry 2009 15 : 23 8.
299. Kessler RC. Epidemiology of women and depression. J Affect Disord 2003 74 : 5 13.
300. Marcus SM. Depression during pregnancy: Rates, risks and consequences - Motherisk Update 2008. Can J Clin Pharmacol 2009 16 : e15 e22.
301. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: The Harvard study of moods and cycles. Arch Gen Psychiatry 2006 63 : 385 390.
302. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006 63 : 375 382.
303. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999 52 : 1214 1220.
304. Li SC, Schoenberg BS, Wang CC, et al. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol 1985 42 : 655 657.
305. Fall PA, Axelson O, Fredriksson M, et al. Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community. J Clin Epidemiol 1996 49 : 637 641.
306. Granieri E, Carreras M, Casetta I, et al. Parkinson's disease in Ferrara, Italy, 1967 through 1987. Arch Neurol 1991 48 : 854 857.
307. Kusumi M, Nakashima K, Harada H, Nakayama H, Takahashi K. Epidemiology of Parkinson's disease in Yonago City, Japan: Comparison with a study carried out 12 years ago. Neuroepidemiology 1996 15 : 201 207.
308. Marttila RJ, Rinne UK. Epidemiology of Parkinson's disease in Finland. Acta Neurol Scand 1976 53 : 81 102.
309. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995 142 : 820 827.
310. Ashok PP, Radhakrishnan K, Sridharan R, Mousa ME. Epidemiology of Parkinson's disease in Benghazi, North-East Libya. Clin Neurol Neurosurg 1986 88 : 109 113. (Pubitemid 16047274)
311. Harada H, Nishikawa S, Takahashi K. Epidemiology of Parkinson's disease in a Japanese city. Arch Neurol 1983 40 : 151 154.
312. Marder K, Tang MX, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998 50 : 1141 1143.
313. Mucchiut M, Belgrado E, Cutuli D, Antonini A, Bergonzi P. Pramipexole-treated Parkinson's disease during pregnancy. Mov Disord 2004 19 : 1114 1115.
314. Becker JB. Estrogen rapidly potentiates amphetamine-induced striatal dopamine release and rotational behavior during microdialysis. Neurosci Lett 1990 118 : 169 171.
315. Becker JB, Beer ME. The influence of estrogen on nigrostriatal dopamine activity: Behavioral and neurochemical evidence for both pre- and postsynaptic components. Behav Brain Res 1986 19 : 27 33.
316. Ohtani H, Nomoto M, Douchi T. Chronic estrogen treatment replaces striatal dopaminergic function in ovariectomized rats. Brain Res 2001 900 : 163 168.
317. Peris J, Decambre N, Coleman-Hardee ML, Simpkins JW. Estradiol enhances behavioral sensitization to cocaine and amphetamine-stimulated striatal [3H]dopamine release. Brain Res 1991 566 : 255 264.
318. Levesque D, Di Paolo T. Rapid conversion of high into low striatal D2-dopamine receptor agonist binding states after an acute physiological dose of 17 beta-estradiol. Neurosci Lett 1988 88 : 113 118.
319. Morissette M, Levesque D, Belanger A, Di Paolo T. A physiological dose of estradiol with progesterone affects striatum biogenic amines. Can J Physiol Pharmacol 1990 68 : 1520 1526.
320. Shieh KR, Yang SC. Effects of estradiol on the stimulation of dopamine turnover in mesolimbic and nigrostriatal systems by cocaine- and amphetamine-regulated transcript peptide in female rats. Neuroscience 2008 154 : 1589 1597.
321. Dluzen DE, Anderson LI. Estrogen differentially modulates nicotine-evoked dopamine release from the striatum of male and female rats. Neurosci Lett 1997 230 : 140 142.
322. McDermott JL, Liu B, Dluzen DE. Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice. Exp Neurol 1994 125 : 306 311. (Pubitemid 24076109)
323. McDermott JL. Effects of estrogen upon dopamine release from the corpus striatum of young and aged female rats. Brain Res 1993 606 : 118 125.
324. Myers RE, Anderson LI, Dluzen DE. Estrogen, but not testosterone, attenuates methamphetamine-evoked dopamine output from superfused striatal tissue of female and male mice. Neuropharmacology 2003 44 : 624 632.
325. Xiao L, Becker JB. Effects of estrogen agonists on amphetamine-stimulated striatal dopamine release. Synapse 1998 29 : 379 391.
326. Dluzen DE, Ramirez VD. Progesterone effects upon dopamine release from the corpus striatum of female rats. I. Evidence for interneuronal control. Brain Res 1989 476 : 332 337.
327. Dluzen DE, Ramirez VD. In vitro progesterone modulates amphetamine-stimulated dopamine release from the corpus striatum of castrated male rats treated with estrogen. Neuroendocrinology 1990 52 : 517 520.
328. Cabrera RJ, Navarro CE. Progesterone in vitro increases NMDA-evoked [3H] dopamine release from striatal slices in proestrus rats. Neuropharmacology 1996 35 : 175 178.
329. de Souza Silva MA, Topic B, Huston JP, Mattern C. Intranasal administration of progesterone increases dopaminergic activity in amygdala and neostriatum of male rats. Neuroscience 2008 157 : 196 203.
330. Nguyen T, Porter J, Svec F. Dehydroepiandrosterone (DHEA) decreases open-field spontaneous activity of Zucker rats. Physiol Behav 1999 67 : 725 731.
331. Bosse R, Di Paolo T. Dopamine and GABAA receptor imbalance after ovariectomy in rats: Model of menopause. J Psychiatry Neurosci 1995 20 : 364 371.
332. Levesque D, Di Paolo T. Chronic estradiol treatment increases ovariectomized rat striatal D-1 dopamine receptors. Life Sci 1989 45 : 1813 1820.
333. Levesque D, Di Paolo T. Dopamine receptor reappearance after irreversible receptor blockade: Effect of chronic estradiol treatment of ovariectomized rats. Mol Pharmacol 1991 39 : 659 665.
334. Di Paolo T, Falardeau P. Modulation of brain and pituitary dopamine receptors by estrogens and prolactin. Prog Neuropsychopharmacol Biol Psychiatry 1985 9 : 473 480.
335. Falardeau P, Di Paolo T. Regional effect of estradiol on rat caudate-putamen dopamine receptors: Lateral-medial differences. Neurosci Lett 1987 74 : 43 48.
336. Levesque D, Gagne B, Barden N, Di Paolo T. Chronic estradiol treatment increases anterior pituitary but not striatal D2 dopamine receptor mRNA levels in rats. Neurosci Lett 1992 140 : 5 8.
337. Zsarnovszky A, Scalise TJ, Horvath TL, Naftolin F. Estrogen effects on tyrosine hydroxylase-immunoreactive cells in the ventral mesencephalon of the female rat: Further evidence for the two cell hypothesis of dopamine function. Brain Res 2000 868 : 363 366.
338. Guerra-Araiza C, Miranda-Martinez A, Neri-Gomez T, Camacho-Arroyo I. Sex steroids effects on the content of GAD, TH, GABA(A), and glutamate receptors in the olfactory bulb of the male rat. Neurochem Res 2008 33 : 1568 1573.
339. Kritzer MF, Adler A, Bethea CL. Ovarian hormone influences on the density of immunoreactivity for tyrosine hydroxylase and serotonin in the primate corpus striatum. Neuroscience 2003 122 : 757 772.
340. Tripanichkul W, Jaroensuppaperch EO, Finkelstein DI. Estrogen enhances the number of nigral dopaminergic neurons of adult male mice without affecting nigral neuroglial number and morphology. Neurosci Lett 2008 435 : 210 214.
341. D'Astous M, Mendez P, Morissette M, Garcia-Segura LM, Di Paolo T. Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Mol Pharmacol 2006 69 : 1492 1498.
342. D'Astous M, Morissette M, Di Paolo T. Effect of estrogen receptor agonists treatment in MPTP mice: Evidence of neuroprotection by an ER alpha agonist. Neuropharmacology 2004 47 : 1180 1188.
343. Xu K, Xu Y, Brown-Jermyn D, et al. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 2006 26 : 535 541.
344. Dluzen DE, McDermott JL, Anderson LI. Tamoxifen diminishes methamphetamine-induced striatal dopamine depletion in intact female and male mice. J Neuroendocrinol 2001 13 : 618 624.
345. Liu LX, Chen WF, Xie JX, Wong MS. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Neurosci Res 2008 60 : 156 161.
346. Shughrue PJ. Estrogen attenuates the MPTP-induced loss of dopamine neurons from the mouse SNc despite a lack of estrogen receptors (ERalpha and ERbeta). Exp Neurol 2004 190 : 468 477.
347. Tripanichkul W, Sripanichkulchai K, Finkelstein DI. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication. Brain Res 2006 1084 : 28 37.
348. Quesada A, Lee BY, Micevych PE. PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev Neurobiol 2008 68 : 632 644.
349. Quesada A, Micevych PE. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions. J Neurosci Res 2004 75 : 107 116.
350. Ferraz AC, Xavier LL, Hernandes S, et al. Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine. Brain Res 2003 986 : 200 205.